Search the PBPK Model Repository

Quickly find freely available drug and population models in our PBPK model repository.

The models provided have been collated from published examples which authors have shared in our Published Model Collection or developed as part of various global health projects in our Global Health Collection. This search facility searches both model collections simultaneously.

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

|<

<

12

13

14

15

16

17

18

19

20

21

22

23

24

25

>

>|

Found 108 Matches

Amodiaquine
Model Files Publication

Brand Name(s) include: Basoquin, Camoquin, Flavoquin, Coarsucam

Disease: Malaria

Drug Class: Antimalarials

Date Updated: June 2021

The model at-a-glance

  Absorption Model

First-Order

  Volume of Distribution

Full PBPK (Method 2)

  Route of Elimination

CYP2C8 = 72%; Additional HLM = 28%

  Perpetrator DDI
  • CYP2D6 

  Validation

  • Four clinical studies describing single and multiple dose exposure of amodiaquine were used to verify the PBPK model. In comparison of predicted vs. observed AUC, 75% of the studies were 2-fold and 50% were within 1.5-fold. A clinical DDI study where amodiaquine was the victim of a CYP2C8-mediated DDI was accurately recovered using the PBPK model.

  Limitations
  • Clinical data has not been used to verify amodiaquine as a perpetrator of CYP2D6-mediated DDIs

  Updates in V19
  • Updated in vitro­ data
    • fu: 0.033 -> 0.089
    • B:P: 1.3 -> 1.1
    • DEAQ Ki for CYP2D6 (µM) – 1.7 -> 1.6
  • Converted from minimal PBPK model to full PBPK model
    • Recalculated retrograde clearance for CYP2C8 CLint and additional HLM CLint

 

Search Score: 1
Tramadol_V14R1_AstraZeneca_20200427
Model Files Publication
Tramadol adult compound file for pediatric prediction. The following parameters need to be updated, as compared to Table 2 in the manuscript: CYP2D6 0.7, CYP3A4 0.035, CYP2B6 0.1, CLr 6.6 L/hr
Search Score: 1
Ertugliflozin_V15R1_Pfizer_20220726
Model Files Publication
Ertugliflozin compound file, UGT1A9 and UGT2B4/7 substrate. Model developed and verified using ADME, IV PK and SD/MD clinical data. Simulated DDI with UGT inhibitor mefenamic acid. https://ascpt.onlinelibrary.wiley.com/doi/full/10.1002/psp4.12581
Search Score: 1
ItraconazoleAndTwoMetabolites_V17R1_AstraZeneca_20191113
Model Files Publication
Capsule and solution formulation of itraconazole in different compound files. 2 Metabolites: OH-itraconazole and KETO-itraconazole. Note: If you wish to add both itraconazole metabolites then itraconazole has to be placed as substrate. https://doi.org/10.1124/dmd.118.081364
Search Score: 1

|<

<

12

13

14

15

16

17

18

19

20

21

22

23

24

25

>

>|